IPSEN S A/S (OTCMKTS:IPSEY) Downgraded by Barclays

IPSEN S A/S (OTCMKTS:IPSEY) was downgraded by equities research analysts at Barclays from an “overweight” rating to an “equal weight” rating in a note issued to investors on Monday, Briefing.com Automated Import reports.

Separately, ValuEngine upgraded shares of IPSEN S A/S from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Five analysts have rated the stock with a hold rating, The stock currently has an average rating of “Hold”.

OTCMKTS:IPSEY opened at $23.26 on Monday. The firm’s fifty day simple moving average is $26.76 and its 200 day simple moving average is $28.05. The stock has a market cap of $7.80 billion, a P/E ratio of 13.37 and a beta of 0.56. IPSEN S A/S has a twelve month low of $21.94 and a twelve month high of $35.97.


Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.

Featured Article: 12b-1 Fees

Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.